Imipramine and citalopram reverse corticosterone-induced alterations in the effects of the activation of 5-HT(1A) and 5-HT(2) receptors in rat frontal cortex.
Using extracellular recording we studied changes in the reactivity of rat frontal cortical slices to the 5-HT(1A), 5-HT(2) and 5-HT(4) receptor agonists, (+/-)-2-dipropyloamino-8-hydroxy-1,2,3,4-tetrahydronaphtalene hydrobromide (8-OH-DPAT), (+/-)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI) and zacopride, respectively, induced by an earlier treatment of animals with corticosterone lasting 1 or 3 weeks. Spontaneous bursting activity was recorded in ex vivo slices incubated in a medium devoid of Mg(2+) ions and containing picrotoxin (30 microM). Repetitive, but not single, corticosterone administration resulted in an attenuation of the effect of the activation of 5-HT(1A) receptors and in an enhancement of the effect related to 5-HT(2) receptors. The effect of 5-HT(4) receptor activation remained unchanged. In separate two sets of experiments rats were treated with corticosterone for 3 weeks and additionally with imipramine or citalopram, beginning on the eighth day of corticosterone administration. In the corticosterone plus imipramine as well as corticosterone plus citalopram groups the effects of 8-OH-DPAT and DOI were not different from control indicating that corticosterone-induced functional modifications in the reactivity of 5-HT(1A) and 5-HT(2) receptors were reversed by antidepressant treatments.
Zahorodna
A
A
Department of Physiology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland.
Hess
G
G
D017371:8-Hydroxy-2-(di-n-propylamino)tetralin / Q000494:pharmacology; D000662:Amphetamines / Q000494:pharmacology; D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology*; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology*; D001549:Benzamides; D019086:Bridged Bicyclo Compounds, Heterocyclic; D015283:Citalopram / Q000494:pharmacology*; D003345:Corticosterone / Q000494:pharmacology*; D003863:Depression / Q000188:drug therapy / Q000503:physiopathology; D005625:Frontal Lobe / Q000187:drug effects; D007099:Imipramine / Q000494:pharmacology*; D008297:Male; D023421:Models, Animal; D051381:Rats; D017208:Rats, Wistar; D044282:Receptor, Serotonin, 5-HT1A / Q000187:drug effects*; D044348:Receptors, Serotonin, 5-HT2 / Q000187:drug effects*; D044422:Receptors, Serotonin, 5-HT4 / Q000187:drug effects; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D013315:Stress, Psychological
D000662:Amphetamines; D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D001549:Benzamides; D019086:Bridged Bicyclo Compounds, Heterocyclic; D044348:Receptors, Serotonin, 5-HT2; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D015283:Citalopram; D044282:Receptor, Serotonin, 5-HT1A; D044422:Receptors, Serotonin, 5-HT4; D017371:8-Hydroxy-2-(di-n-propylamino)tetralin; C055971:zacopride; D007099:Imipramine; C015952:4-iodo-2,5-dimethoxyphenylisopropylamine; D003345:Corticosterone